Key result
The continuous-flow total artificial heart demonstrated effective sensorless speed control, self-regulation maintaining atrial pressure differences within ±10 mm Hg, and acceptable hemolysis levels.
Population
Preclinical models including calf blood for hemolysis testing and computational models (EMAG/CFD)
Design
Preclinical
Authors
Loading...
Supports further preclinical refinement of continuous-flow total artificial hearts; leaves open clinical translation.
The Cleveland Clinic continuous-flow total artificial heart demonstrated promising preclinical performance in speed control, self-regulation, and hemolysis, supporting further device development.
Kobayashi et al. (2012) studied this question. Continuous-flow total artificial heart was evaluated on Device performance including speed control, self-regulation, and hemolysis. The continuous-flow total artificial heart demonstrated effective sensorless speed control, self-regulation maintaining atrial pressure differences within ±10 mm Hg, and acceptable hemolysis levels.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: